Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy - Wikidata - wikimedia - TriplyDB

Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy

Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy

http://www.wikidata.org/entity/Q35558292

about

Advances in antibiotic therapy in the critically ill Renal replacement therapy in acute kidney injury: controversy and consensus Optimizing antimicrobial therapy in critically ill patients Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies.Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: a comparative study.β-lactam antibiotic concentrations during continuous renal replacement therapy.Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.Beta-lactam antibiotic dosing during continuous renal replacement therapy: how can we optimize therapy?Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?Duration of antibiotic therapy in bacteraemia.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Treatment of bloodstream infections in ICUs A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit.SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider.Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Case-control study of drug monitoring of β-lactams in obese critically ill patients.Antimicrobial dosing in acute renal replacement.Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.Year in review 2010: Critical Care--Infection.Permissive hypofiltration.Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Compliance With Institutional Antimicrobial Dosing Guidelines in Patients Receiving Continuous Venovenous Hemodialysis.Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".We Underdose Antibiotics in Patients on CRRT.Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations.Early management of sepsis.Use of high-volume haemodiafiltration in patients with refractory septic shock and acute kidney injury.Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]

P2860

Q26749328-0D58384D-8BB1-4460-A246-DD67B0CE309E Q26998864-8206DD8D-2309-4AD7-9FFD-10374261CF89 Q26999905-97CFCFAA-DFEF-4031-B864-49AFA673CD43 Q27313917-1A0D5080-BE0B-4337-B71C-00374F2FC304 Q33734676-FFC37111-2D79-4B99-873F-5E5845578254 Q33821438-FC14F797-C7A3-4073-8B46-4645D0071892 Q33821554-1BE2E999-5431-47CB-8470-F94CD274DE5A Q33821937-1C58CAF3-9C83-4E72-A339-A2DB591BB4E4 Q33821972-DED13107-CB1D-405D-A7C4-625E67AD8718 Q34246286-239AEF88-47C4-4C11-B09D-1CA3AF0F9BB9 Q34274190-1DF58A9C-C24B-43EE-9F17-8E0470757432 Q34327857-DE7C2F65-23AF-4311-86C7-3029A7A6D5AE Q34894900-7501D30A-DB45-4329-B54E-92BF34D0A746 Q34896896-0C0DB93D-F67E-40C2-9953-F81AADB748F8 Q35504097-35098D72-1C9E-4838-8017-2E7B730CB53B Q35819409-F48621D9-40F1-436F-B9BF-E2B8C14B78A5 Q35827280-02E95129-846D-4AA1-A357-275370CE322C Q35867327-06DB1D88-31F7-4013-8254-1BC9893D38F0 Q35921350-6A942C6A-C3BF-44DF-8419-4B9A1313F093 Q35942407-D30366E2-2E11-4DF5-B96A-61B4089A4E08 Q35960694-DC4E6F9B-C0FF-4B58-BFD7-FBF13B11C880 Q36070363-45A71D28-840D-4813-9FC7-8DBA9705D850 Q36287127-08375C66-E002-4E20-A1AB-561E0E9C2D8A Q36558332-82A8CCF2-651D-4988-85CE-FF96FB27B53F Q37252494-D572CAD9-5B0D-41FC-B35C-D0AC56EDE119 Q37643628-2485CE90-A5B6-4EEA-A228-3EE13AAB450E Q37966018-A2DDDFC1-9114-4129-A4E9-DD73DFA34E6C Q38030054-67274BEC-05DB-4BFD-8AA2-611B8293CAEA Q38070907-A293A205-CE8C-438C-8CD3-5115D64B4D44 Q38138835-F5956377-65DE-4F12-8BDC-554A02FE0F13 Q38181340-63D47C8E-4DF2-4AB3-BB3E-4BB1D05CF2FE Q38261172-1222DDEF-7DDB-4DFF-A886-132641DEB5E1 Q38809129-6C04A57E-221C-49BB-9BEA-B2DE197A1A06 Q38916254-0E64FC76-2068-49FA-B7EE-3469F700E337 Q38983475-2642EB7D-8AFD-43DF-A170-8894C16EF0B6 Q39210514-9EB75170-AF0E-43F5-A930-C1EE40190C08 Q39965478-62CF5DE5-3AF9-4053-9C63-FD1DAB57F28F Q40233756-D557CEA6-6EDB-43A1-A54D-0CFCC474BBF3 Q40445718-B40B7E8D-0AB8-4BC1-B105-3E2010C3DFDC Q40541397-D4281C3B-9918-434A-9953-47D769DFE2AC

P2860

Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy

http://www.wikidata.org/entity/Q35558292

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Recommended β-lactam regimens ...... uous renal replacement therapy

@ast

Recommended β-lactam regimens ...... uous renal replacement therapy

@en

type

label

Recommended β-lactam regimens ...... uous renal replacement therapy

@ast

Recommended β-lactam regimens ...... uous renal replacement therapy

@en

prefLabel

Recommended β-lactam regimens ...... uous renal replacement therapy

@ast

Recommended β-lactam regimens ...... uous renal replacement therapy

@en

P1433

Q35558292-6ADAC440-78D2-495E-9EDA-980AA2A6949C

P1476

Q35558292-D354E459-552A-4979-A925-7496DD0A4B79

P2093

Q35558292-03F4D331-07E4-444A-8442-CD6D37B57F18

Q35558292-57625641-E5CD-4AEB-98F1-7CFE2B6C1350

Q35558292-830DA799-040A-4F47-9382-888F4C24AD3E

Q35558292-D27D666B-FCF4-43B6-978C-821BB4691A51

Q35558292-EFF013E2-DAAB-4285-976F-C338888624CE

Q35558292-FB0B61C7-B790-4F70-8C8C-8E0650ADB0A6

P2860

Q35558292-0011D422-6F43-4827-885B-0BB9D467C86D

Q35558292-071103CB-37BC-4AC6-A4D2-EFC8FB4DECD7

Q35558292-07C9B001-13DE-44FC-8848-68691E0A8386

Q35558292-0F61AC8F-109C-4898-B3BA-506F9F4E6709

Q35558292-12B3A6F8-8115-4C59-ACE7-044AB4A14C17

Q35558292-18D5405D-8A9B-422C-B9C2-F2F1413EFB58

Q35558292-1A5CC7FB-7719-440B-BF70-4AB022BF7191

Q35558292-2B38FD63-70E8-4E80-8920-7FC55890BA04

Q35558292-2CC94F38-CE32-432B-B6BB-5FF71CE8891B

Q35558292-35526039-C47C-4E86-851F-192B5FF0F2F8

P2888

Q35558292-F86F5FEA-4837-4B71-BD9D-0D541BA0C422

P304

Q35558292-DFD3AC23-24CB-4F1A-B213-B5AAE4EF00C9

P31

Q35558292-372E6B82-6ACB-4989-A0EE-A624C0D6AEFC

P356

Q35558292-FCA74799-3566-4A32-94BE-71B3ECE207D0

P433

Q35558292-8DD2351C-3F48-48FB-BE38-C7B799317818

P478

Q35558292-88A15BEB-41CE-48DF-8746-A1617849B5DB

P50

Q35558292-00D3AE44-D16D-4791-82E5-25F3A07CC714

P577

Q35558292-204AC377-7DFF-4525-8673-F7BFF348C49E

P5875

Q35558292-1E4DEA0C-63CD-488C-BEE0-EAC41D7CA639

P6179

Q35558292-2DB97765-60D4-43C7-800B-3272E857BF1D

P698

Q35558292-5B2B9F4A-B255-42AF-BAA9-968CF18B26DF

P921

Q35558292-CD91A1BB-941E-407C-ADA4-AC4F025B089D

P932

Q35558292-5FA0E255-5449-4EDA-9AA4-BA49EBC7AD7C

P356

P1433

P1476

Recommended β-lactam regimens ...... uous renal replacement therapy

@en

P2093

Daniel De Backer

http://www.w3.org/2001/XMLSchema#string

Fabio Silvio Taccone

http://www.w3.org/2001/XMLSchema#string

Frédéric Cotton

http://www.w3.org/2001/XMLSchema#string

Frédérique Jacobs

http://www.w3.org/2001/XMLSchema#string

Lucie Seyler

http://www.w3.org/2001/XMLSchema#string

Pascale Macours

http://www.w3.org/2001/XMLSchema#string

P2860

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.

Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing

Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.

Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

P2888

P304

R137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC10257

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Louis Vincent

P577

2011-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51199234

http://www.w3.org/2001/XMLSchema#string

P6179

1005923181

http://www.w3.org/2001/XMLSchema#string

P698

21649882

http://www.w3.org/2001/XMLSchema#string

P921

P932

3219006

http://www.w3.org/2001/XMLSchema#string